Back
Denali Therapeutics 10K Form
Sell
20
DNLI
Denali Therapeutics
Last Price:
15.55
Seasonality Move:
5.93%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-08-07 | 10Q | DNLI/Denali Therapeutics Quarterly |
| 2020-05-07 | 10Q | DNLI/Denali Therapeutics Quarterly |
| 2020-02-27 | 10K | DNLI/Denali Therapeutics Annual |
| 2019-11-06 | 10Q | DNLI/Denali Therapeutics Quarterly |
| 2019-08-06 | 10Q | DNLI/Denali Therapeutics Quarterly |
| 2019-05-08 | 10Q | DNLI/Denali Therapeutics Quarterly |
Receive DNLI News And Ratings
See the #1 stock for the next 7 days that we like better than DNLI
DNLI Financial Statistics
Sales & Book Value
| Annual Sales: | $330.53M |
|---|---|
| Cash Flow: | $-100.89M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $7.45 |
| Price / Book: | 2.15 |
Profitability
| EPS (TTM): | -1.08000 |
|---|---|
| Net Income (TTM): | $-145.22M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Denali Therapeutics Earnings Forecast
Key Denali Therapeutics Financial Ratios
- The Research & Development expenses have been 128.24% of Revenue.
- The Net Earning history of DNLI is -43.94% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 4 years.
Denali Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | DNLI |
| CUSIP: | 24823R |
| Website: | denalitherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
DNLI Technical Analysis vs Fundamental Analysis
Sell
20
Denali Therapeutics (DNLI)
is a Sell
Is Denali Therapeutics a Buy or a Sell?
-
Denali Therapeutics stock is rated a Sell
The current Denali Therapeutics [DNLI] share price is $15.56. The Score for DNLI is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.